# Overexpression ofYKL-39 Gene in Glial Brain Tumors

Authors: Vadym Kavsan; Vladimir Dmitrenko; Oxana Boyko; Valery Filonenko; Stanislav Avdeev; Pavel Areshkov; Andriy Marusyk; Tatiana Malisheva; Vladimir Rozumenko; Yury Zozulya
Journal: Scholarly Research Exchange
 (2008)

---

## Abstract

More than forty genes with considerably increased expression in glioblastoma as compared to normal human brain were identified by SAGE. One of the most prominent among them wasCHI3L2 (YKL-39) gene, which encodes 39 kDa chitinase-like protein. Northern blot hybridization confirmed the data of SAGE for the majority of glioblastomas. Anaplastic astrocytomas could be divided on two groups: in one of them the YKL-39 expression was completely undetectable, but in the other group quite high contents of YKL-39 mRNA were detected. In this study, preliminary data show that patients with undetectable expression of YKL-39 in anaplastic astrocytomas did not have recurrent tumors quite long (more than 2-3 years) period of time. YKL-39 RNA has not been detected in diffuse astrocytomas and in all (but one) samples of normal brain. Increased expression of YKL-39 gene in glioblastomas was shown also at the protein level. Western blots did not shown simultaneous production of
YKL-39 and  YKL-40, in spite of having high degree of their sequence identity.   Increased expression of YKL-39 in subsets of patients with glial tumors, reported here for the first time,
together with abnormal increase of the YKL-40 gene expression may be a novel molecular marker for glial tumors.


---

## Body

## 1. Introduction

Human brain tumors are often characterized by
significant aggressiveness, high invasiveness, and neurological
destructiveness. Almost half of all the intracranial tumors are gliomas, the
majority of which are astrocytic gliomas, they are considered to be one of the
most lethal forms of malignant tumors. The tumors progress through series of
histopathological stages, associated with accumulation of genetic abnormalities
on different chromosomes and with changes in gene expression [1]. One of the
specific features of these tumors is high morphologic heterogeneity which
occurs to be the result of multiple genetic pathways of their initiation and
progression [2]. Histological identification of astrocytomas may be complicated
or subjective, resulting in misdiagnosis, especially in cases when the typical
picture is absent. Standard treatments of malignant gliomas including surgery,
chemo- or radiotherapy are relatively nonspecific and may be applied to all
glioma subtypes. However, despite advances in these treatments, the overall
prognosis for patients with high-grade brain tumors remains dismal.Development of molecular biomarkers and
molecular therapeutics forms the basis for the personalized cancer medicine in
the 21st century. Progress in tumor molecular biology offers the
opportunity to direct therapies to specific molecular markers and cellular
signaling pathways involved in oncogenesis. This offers the potentials to
tailor treatment of tumor subtypes—perhaps with greater efficacy and less
toxicity. However, at present there exist only a handful of tumor markers that
are being routinely used by physicians. Many other potential markers are still
being researched. High heterogeneity and multiple pathways of glioma development
challenge discovery of new molecular markers for more detailed and precise tumor
subtyping.In an effort to identify the genes, which might be used as molecular markers for glial tumors, we compared gene
expression in glioblastoma, the most common
and aggressive malignant brain tumor, and normal adult
human brain by Serial Analysis of Gene Expression (SAGE) [3]. Obtained results
demonstrated that 44 genes were expressed at the significantly higher level in
tumors compared to the normal brain cells. One of such genes overexpressed in
glioblastoma is CHI3L2 (YKL-39), encoding the secreted chitinase-like protein, which has
a molecular weight of 39 kDa and is a member of the 18 glycosyl hydrolase
family [4].The present study was initiated to examine the expression ofYKL-39 in independent sets of glioma
samples at both RNA and protein levels. However, the use of single clinical
factors as markers will be substituted soon by systematic approach, including
multiple factors, both molecular biological and genetic. So, the purpose of the
research in future is the development of the so-called cDNA-panels, which include
a number of genes with significantly changed expression in tumors and which can
be used for molecular typing of human brain tumors and determination of certain
molecular variants for the tumors of identical histological type.


## 2. Materials and Methods

### 2.1. Patients

Sixty one patients with different brain tumors (28
glioblastomas, 16 anaplastic astrocytomas, 7 diffuse astrocytomas, 3 oligodendrogliomas, 3 anaplastic oligoastrocytomas, 1 sarcomatous meningioma, 1
metastatic cancer, 1 neuroblastoma, and 1
angioblastoma), classified on the basis of review of haematoxylin and eosin-stained sections of
surgical specimens according to WHO criteria [5], were
enrolled in this study. 12 surgical
specimens of histologically normal brain tissue adjacent to tumors were used as
a source of normal adult human brain RNA and protein. All patients were being treated at the hospital of
A.P. Romodanov Institute of Neurosurgery (Kiev, Ukraine). The study protocol was approved by the human ethics review committee
of both institutions, and signed consent forms from patients were
obtained.


### 2.2. Serial Analysis of Gene Expression (SAGE)

Comparison of gene expression in glioblastoma with that of normal human brain was provided by
accessing SAGE NCBI web sitehttp://www.ncbi.nlm.nih.gov/SAGE/ and using the
search tool of Digital Gene Expression Displayer (DGED) [6, 7].


### 2.3. Preparation ofYKL-39 cDNA and Construction of Recombinant Plasmid

The tissue samples were stored at −70°C
until analysis. RNA was extracted from frozen samples as described in our
previous works [3, 8] according to the
acid-guanidinium thiocyanate-phenol-chloroform method [9], andthen
converted to cDNA by reverse transcription and oligo(dT) priming. The DNA fragment
encoding YKL-39 was amplified by a polymerase chain
reaction (PCR) from the cDNA sample using forward primer YKL39expfor
(5′-ATCATATGGGAGCAA-CCACCATG-3′) and reverse primer YKL39exprev
(5′-ATCTCGAGCA-GGGAGCCAAGGCTTCTCTT-3′) with additional nucle-otides on 5′end for generation of restriction sites CATATG (Nde I) and CTCGAG (Xho I). PCR was performed under the followingconditions: 30 cycles at 94°C for 1 minute, 56°C for 1 minute, and 72°C for 1.5 minutes. The
amplified DNA was then cloned ina plasmid vector pGemT-Easy (Promega, USA).


### 2.4. Northern Blot Hybridization

Total RNA was fractionated by electrophoresis
(10μg per lane) in a 1.5% agarose gel
containing 2,2 M formaldehyde in borate buffer (0,2 mM EDTA, pH 8,0/30 mM boric acid/3, 3 mM sodium tetraborate, pH 7,5), and then transferred to a Hybond-N nylon
membrane (Amersham Pharmacia Biotech, Austria). YKL-39 PCR-product synthesized on the
template of recombinant plasmid pET-24a(+)-YKL-39 by
random priming in presence of [α-P32] dCTP (Amersham
Biosciences, Austria) was used as a hybridization probe. Membranes were incubated with P32-labeled cDNA probe in 50% formamide/5xSSC/5xDenhardt's
solution/0.1% SDS/100 mg/ml salmon sperm DNA at 42°C overnight. Extensive
washing was performed: twice with 2xSSC/0.1% SDS for 15 minutes at room
temperature, once with 2 x SSC/0.1% SDS for 30 minutes at 65°C, and
finally with 0.2xSSC/0.1% SDS for 30 minutes at 65°C. Subsequently,
the membranes were exposed to radiographic film with an intensifying screen at
−70°C. The membranes were stripped and rehybridized with a P32-labelled human β-actin cDNA probe as a control of RNA gel loading. Hybridization
bands were normalized to β-actin and compared by densitometry of
hybridization signals using the Scion Image 1.62c program.


### 2.5. Preparation of Recombinant Protein YKL-39 and Polyclonal Antibody

After restriction of pGemT-Easy-YKL-39, the Nde I/Xho I fragment was subcloned in
expression vector pET-24a(+) (Novagen, Germany). The map of recombinant plasmid pET-24a(+)-YKL-39, nucleotide, and protein sequence of YKL-39 are presented in Figure 1. The nucleotide sequence was checked by the
dideoxy method (3130 Genetic Analyzer, Applied Biosystems, USA). E. coli (BL21, DE3) cells transformed by recombinant plasmid pET-24a(+)-YKL-39 were grown at 37°C to optical density 0,5–0,7 (600 nm) and
synthesis of recombinant protein was induced during 3 hours by 1 mM IPTG. Affinity
purification of YKL-39, containing His6 at the C-terminus,
was carried out on Ni-NTA agarose (Ni2+-charged nitriloacetic
acid-modified agarose) under denaturing conditions in the presence of 8 M urea
according to manufacturer’s protocol (Qiagen, USA). Protein products were analyzed by 12%
SDS-PAGE and Coomassie Brilliant Blue R-250 staining.Recombinant plasmid pET-24a(+)-YKL-39, nucleotide, and amino-acid sequences of YKL-39 (GenBank Ac N: NM_004000). Oligonucleotide PCR primers are shown by arrows.
(a)(b)Rabbit antiserum was raised againstEscherichia
coli-expressed His6-fusion protein YKL-39 as described earlier
[10] with some modifications. Male rabbits (2-3 kg) were inoculated 10 times subcutaneously
along spinal cord with purified recombinant YKL-39-His6 protein (30 μg each time) emulsified in PBS with 50% Freund’s
complete adjuvant (Sigma, St. Louis, Mo, USA). Two more immunizations were
repeated in eight and four week intervals by the same antigen quantities in the
presence of 50% Freund’s incomplete adjuvant. Five days after the final boost,
blood was collected by cardiac puncture. Serum was obtained after overnight
incubation of blood at 4°C and centrifugation at 1000 g for 15 minutes.
YKL-39 antibody titer in serum was determined by enzyme-linked
immunosorbent assay (ELISA).


### 2.6. Protein Extraction from Brain Tissue and Western Blot Analysis

Total protein extracts of the brain tissues were
obtained by grinding of frozen tissue in ceramic mortar and subsequent homogenization
in 100 mM  Tris-HCl, pH 7,5/100 mM NaCl/0,5% sodium deoxycholate with mixture of protease
inhibitors (Boehringer Mannheim, Germany) on ice using a Dounce homogenizer and stored at −20°C until use. After centrifugation the protein
concentration in the supernatant was determined by Bradford method [11].Western blotting was performed as
described by Burnette [12]. Briefly, 40 μg
protein samples were fractionated by 12% SDS-PAGE
and then electrophoretically transferred to
nitrocellulose membrane (Amersham Pharmacia Biotechnology, Austria) in Criterion Blotter (Bio-Rad,
USA) at 250 mA during 75 minutes. Nonspecific membrane
binding was blocked by 5% solution of dry fat-free milk in PBST for 1 hour at
room temperature. The membrane was incubated for 1 hour with anti-YKL-39 polyclonal antibody, 1:300 dilution in 5% dry
fat-free milk-PBST for 1 hour. The membrane was washed three times in PBST, 5
minutes each, and incubated with the secondary antirabbit antibody, horseradish peroxidase conjugated, 1:20000 dilution (Promega, USA)
for 1 hour. Again, the membrane was washed three times in PBST, and
antibody-bound protein was detected by adding enhanced chemiluminescence
reagent-Luminol (Amersham Pharmacia Biotechnology, Austria)
with hydrogen peroxide and exposing the membrane to Agfa film (Belgium).
Western blotting with commercial anti-YKL-40 antibody, 1:5000 dilution, (Quidel
Corporation, USA) was performed by the same way.


## 2.1. Patients

Sixty one patients with different brain tumors (28
glioblastomas, 16 anaplastic astrocytomas, 7 diffuse astrocytomas, 3 oligodendrogliomas, 3 anaplastic oligoastrocytomas, 1 sarcomatous meningioma, 1
metastatic cancer, 1 neuroblastoma, and 1
angioblastoma), classified on the basis of review of haematoxylin and eosin-stained sections of
surgical specimens according to WHO criteria [5], were
enrolled in this study. 12 surgical
specimens of histologically normal brain tissue adjacent to tumors were used as
a source of normal adult human brain RNA and protein. All patients were being treated at the hospital of
A.P. Romodanov Institute of Neurosurgery (Kiev, Ukraine). The study protocol was approved by the human ethics review committee
of both institutions, and signed consent forms from patients were
obtained.


## 2.2. Serial Analysis of Gene Expression (SAGE)

Comparison of gene expression in glioblastoma with that of normal human brain was provided by
accessing SAGE NCBI web sitehttp://www.ncbi.nlm.nih.gov/SAGE/ and using the
search tool of Digital Gene Expression Displayer (DGED) [6, 7].


## 2.3. Preparation ofYKL-39 cDNA and Construction of Recombinant Plasmid

The tissue samples were stored at −70°C
until analysis. RNA was extracted from frozen samples as described in our
previous works [3, 8] according to the
acid-guanidinium thiocyanate-phenol-chloroform method [9], andthen
converted to cDNA by reverse transcription and oligo(dT) priming. The DNA fragment
encoding YKL-39 was amplified by a polymerase chain
reaction (PCR) from the cDNA sample using forward primer YKL39expfor
(5′-ATCATATGGGAGCAA-CCACCATG-3′) and reverse primer YKL39exprev
(5′-ATCTCGAGCA-GGGAGCCAAGGCTTCTCTT-3′) with additional nucle-otides on 5′end for generation of restriction sites CATATG (Nde I) and CTCGAG (Xho I). PCR was performed under the followingconditions: 30 cycles at 94°C for 1 minute, 56°C for 1 minute, and 72°C for 1.5 minutes. The
amplified DNA was then cloned ina plasmid vector pGemT-Easy (Promega, USA).


## 2.4. Northern Blot Hybridization

Total RNA was fractionated by electrophoresis
(10μg per lane) in a 1.5% agarose gel
containing 2,2 M formaldehyde in borate buffer (0,2 mM EDTA, pH 8,0/30 mM boric acid/3, 3 mM sodium tetraborate, pH 7,5), and then transferred to a Hybond-N nylon
membrane (Amersham Pharmacia Biotech, Austria). YKL-39 PCR-product synthesized on the
template of recombinant plasmid pET-24a(+)-YKL-39 by
random priming in presence of [α-P32] dCTP (Amersham
Biosciences, Austria) was used as a hybridization probe. Membranes were incubated with P32-labeled cDNA probe in 50% formamide/5xSSC/5xDenhardt's
solution/0.1% SDS/100 mg/ml salmon sperm DNA at 42°C overnight. Extensive
washing was performed: twice with 2xSSC/0.1% SDS for 15 minutes at room
temperature, once with 2 x SSC/0.1% SDS for 30 minutes at 65°C, and
finally with 0.2xSSC/0.1% SDS for 30 minutes at 65°C. Subsequently,
the membranes were exposed to radiographic film with an intensifying screen at
−70°C. The membranes were stripped and rehybridized with a P32-labelled human β-actin cDNA probe as a control of RNA gel loading. Hybridization
bands were normalized to β-actin and compared by densitometry of
hybridization signals using the Scion Image 1.62c program.


## 2.5. Preparation of Recombinant Protein YKL-39 and Polyclonal Antibody

After restriction of pGemT-Easy-YKL-39, the Nde I/Xho I fragment was subcloned in
expression vector pET-24a(+) (Novagen, Germany). The map of recombinant plasmid pET-24a(+)-YKL-39, nucleotide, and protein sequence of YKL-39 are presented in Figure 1. The nucleotide sequence was checked by the
dideoxy method (3130 Genetic Analyzer, Applied Biosystems, USA). E. coli (BL21, DE3) cells transformed by recombinant plasmid pET-24a(+)-YKL-39 were grown at 37°C to optical density 0,5–0,7 (600 nm) and
synthesis of recombinant protein was induced during 3 hours by 1 mM IPTG. Affinity
purification of YKL-39, containing His6 at the C-terminus,
was carried out on Ni-NTA agarose (Ni2+-charged nitriloacetic
acid-modified agarose) under denaturing conditions in the presence of 8 M urea
according to manufacturer’s protocol (Qiagen, USA). Protein products were analyzed by 12%
SDS-PAGE and Coomassie Brilliant Blue R-250 staining.Recombinant plasmid pET-24a(+)-YKL-39, nucleotide, and amino-acid sequences of YKL-39 (GenBank Ac N: NM_004000). Oligonucleotide PCR primers are shown by arrows.
(a)(b)Rabbit antiserum was raised againstEscherichia
coli-expressed His6-fusion protein YKL-39 as described earlier
[10] with some modifications. Male rabbits (2-3 kg) were inoculated 10 times subcutaneously
along spinal cord with purified recombinant YKL-39-His6 protein (30 μg each time) emulsified in PBS with 50% Freund’s
complete adjuvant (Sigma, St. Louis, Mo, USA). Two more immunizations were
repeated in eight and four week intervals by the same antigen quantities in the
presence of 50% Freund’s incomplete adjuvant. Five days after the final boost,
blood was collected by cardiac puncture. Serum was obtained after overnight
incubation of blood at 4°C and centrifugation at 1000 g for 15 minutes.
YKL-39 antibody titer in serum was determined by enzyme-linked
immunosorbent assay (ELISA).


## 2.6. Protein Extraction from Brain Tissue and Western Blot Analysis

Total protein extracts of the brain tissues were
obtained by grinding of frozen tissue in ceramic mortar and subsequent homogenization
in 100 mM  Tris-HCl, pH 7,5/100 mM NaCl/0,5% sodium deoxycholate with mixture of protease
inhibitors (Boehringer Mannheim, Germany) on ice using a Dounce homogenizer and stored at −20°C until use. After centrifugation the protein
concentration in the supernatant was determined by Bradford method [11].Western blotting was performed as
described by Burnette [12]. Briefly, 40 μg
protein samples were fractionated by 12% SDS-PAGE
and then electrophoretically transferred to
nitrocellulose membrane (Amersham Pharmacia Biotechnology, Austria) in Criterion Blotter (Bio-Rad,
USA) at 250 mA during 75 minutes. Nonspecific membrane
binding was blocked by 5% solution of dry fat-free milk in PBST for 1 hour at
room temperature. The membrane was incubated for 1 hour with anti-YKL-39 polyclonal antibody, 1:300 dilution in 5% dry
fat-free milk-PBST for 1 hour. The membrane was washed three times in PBST, 5
minutes each, and incubated with the secondary antirabbit antibody, horseradish peroxidase conjugated, 1:20000 dilution (Promega, USA)
for 1 hour. Again, the membrane was washed three times in PBST, and
antibody-bound protein was detected by adding enhanced chemiluminescence
reagent-Luminol (Amersham Pharmacia Biotechnology, Austria)
with hydrogen peroxide and exposing the membrane to Agfa film (Belgium).
Western blotting with commercial anti-YKL-40 antibody, 1:5000 dilution, (Quidel
Corporation, USA) was performed by the same way.


## 3. Results and Discussion

Serial Analysis of Gene Expression foundYKL-39 among the most abundant transcripts in glioblastoma, extremely aggressive form of
human brain tumors. It was number one in the
list of 44 genes with more than 5-fold (P≤.05) increased
expression level in glioblastoma. According to results of SAGE, YKL-39 is not expressed at all in adult normal brain but increased its expression in glial tumors of
II–IV grades of malignancy [3].YKL-39 belongs to the protein family of 18 glycosyl hydrolases
(chitinases and chitinase-like proteins). The members of this family have an (αβ)8 barrel structure [13] and include chitotriosidase, a protein secreted from
human macrophages that does have chitinase activity [14], and five proteins
with no presently known enzymatic activity, HC gp-39 (YKL-40) [15], YKL-39 [4], YM-1 [16], oviductal
glycoprotein [17], and SI-CLP, an interacting partner of the endocytic/sorting
receptor stabilin-1 [18]. YKL-39 was found as a protein that co-purified with YKL-40.
This 39-kDa protein has the N-terminal sequence YKL, so it was termed YKL-39.
The 1434-nucleotide sequence of the YKL-39 cDNA predicts a 385-residue initial translation product and a 364-residue
mature YKL-39. YKL-39 lacks the active site glutamate, which is essential for
the activity of chitinases, and as expected has no chitinase activity. YKL-39
is closely related in size and sequence to YKL-40, a 40-kDa glycoprotein [19],
more closely than to other members of this family, but in contrast to
HC gp-39 (YKL-40), YKL-39 is not a
glycoprotein, does not bind to heparin and was not found in macrophages [20]. Same as YKL-39, SAGE
includes HC gp-39 (YKL-40) to the
list of 44 genes with more than 5-fold (P≤.05) increased expression level in glioblastoma as compared
to normal brain [3]. However, the absolute quantity of YKL-39 transcripts is much less in
glioblastomas and normal brain than those for YKL-40.It was shown that high contents of YKL-40 protein in sera of patients
with so different tumors as colorectal cancer [21], recurrent breast cancer [22] and glioblastoma [23] are
associated with a significantly poorer prognosis compared to patients with
normal serum. Taking
into account the lack of similar data for YKL-39 and its high homology to HC
gp-39, the present study was initiated to further analysis of the expression of YKL-39 in brain neoplasms and
especially in glial tumors.Northern hybridization and Western blot analysis were used to confirm SAGE results for
glioblastomas (WHO astrocytoma grade IV), anaplastic astrocytomas (WHO astrocytoma grade III) and diffuse astrocytomas (WHO astrocytoma grade II) (Figure2). In some cases, the Northern
hybridization was performed two-three times with the same sample.  The samples with low signals with human β-actin cDNA probe as a control of RNA gel loading were excluded
from the calculation. Expression of YKL-39 was determined by Northern
analysis in the majority of glioblastomas
(19 of 27 samples analyzed).
Anaplastic astrocytomas were possible to divide on two groups: in one of them,
the YKL-39 expression was completely
undetectable (12 samples), but in other group (4 samples), it was possible to
detect quite high contents of YKL-39 mRNA. YKL-39 RNA has not been detected in eight samples of diffuse astrocytoma under investigation.
Among brain tumors of nonastrocytic origin, YKL-39 mRNA was detected in neuroblastoma and metastatic cancer, but was not detected in three samples of oligodendroglioma, one sample of each anaplastic oligoastrocytoma, angioblastoma, and sarcomatous meningioma.Analysis ofYKL-39 gene expression
in glioblastoma. (A) Northern blot hybridization of P32-YKL-39 cDNA probe with RNA
panel. (B) Northern blot hybridization of P32-β actin cDNA probe with RNA panel. (C) Ethidium bromide-stained agarose gel. (D) Bar graph showing
relative expression level of YKL-39.
Tissue and tumor types are indicated above each lane of the blot, numbers are
the conditional numbers of RNA samples: (a) GB—glioblastoma, NB—human adult normal brain;
(b) GB—glioblastoma, NRB—neuroblastoma, NB—human adult normal brain, AA— anaplastic astrocytoma, A—astrocytoma,
OL—oligodendroglioma; (c) GB—glioblastoma, AA— anaplastic astrocytoma, AOA—anaplastic oligoastrocytoma, OL—oligodendroglioma, A— astrocytoma, MS—meningioma sarcomatous, NB—human adult normal brain, ABL—angioblastoma; (d) NB—human adult normal brain, GB—glioblastoma.
(a)(b)(c)(d)Hybridization showed the presence ofYKL-39 mRNA only in 1 from 13 samples of
normal brain at the
level high enough for the determination by Northern analysis. It should be pointed that the
“normal” brain tissue collected around the tumor samples may serve as a source of normal adult human brain RNA only with some precautions: gliomas are infiltrating
tumors, and scattered tumor cells are present far away from the dense tumor
area removed during surgery. Moreover, inflammation and astrocytic activation
occur in this peritumoral tissue.All 16 anaplastic astrocytomas
analyzed in this work were used for the determination of expression of both
genes. 1 of 4 samples with expressedYKL-39 had no detectable HC gp-39 mRNA; and vice versa 4 of 12
anaplastic astrocytomas, negative as related to YKL-39 mRNA, had the expression of HC gp-39 gene. Interesting that YKL-39 mRNA was detected in one
recurrent tumor (glioblastoma), while in the original anaplastic astrocytoma
expression of both genes it was not detected. Earlier, we showed that
anaplastic astrocytomas can be divided in two groups as it concerns HC gp-39 expression [24]. Patients with high level of HC gp-39 mRNA had shorter
remission period to the secondary surgery than patients with lower level of HC gp-39 expression. Naturally, it is necessary to investigate much more samples, however even preliminary data show that patients with undetectable expression of YKL-39 in anaplastic astrocytomas (6
patients of 12 under investigation) did not have recurrent tumors for a quite long (more than 2-3 years)
period.To analyze the expression ofYKL-39 gene at the protein level, total RNA extracted from glioblastoma cells, was converted to cDNA by reverse transcription and oligo(dT) priming. The DNA fragment encoding YKL-39 was amplified from the cDNA sample and the amplified DNA was then cloned in a plasmid vector pET-24a(+). E. coli transformed with this recombinant
plasmid was used for production of the recombinant (His)6-tagged protein. Purified protein had an expected size (about 40 kDa) although electrophoresis in denatured conditions beside the major band showed a couple of minor bands which apparently are the result of proteolytic hydrolysis. The problems occurred during (His)6-protein purification
by Ni-NTA-agarose, particularly nonspecific oxidation of protein by this
resin, were described also earlier
[23]. The
antibody to the purified recombinant protein was shown to react specifically on
Western blots with purified human YKL-39. Preimmune sera did not react.Western analysis of brain tumors
revealed the 39 kDa product in five of eleven analyzed glioblastoma samples and
in five of thirteen anaplastic astrocytomas, but in
none of five samples of normal brain. High homology of nucleotide and amino acid sequences
of YKL-39 and YKL-40 (Figure3) suppose either some identity of their functions
or at least some coordination of their activity. However, experimental results do not always confirm this hypothesis. For example, expression analysis showed high levels of both
proteins in normal articular chondrocytes, with lower levels of YKL-39 than YKL-40.
However, whereas HC gp-39 was
significantly downregulated in late stage of osteoarthritic chondrocytes, YKL-39 was significantly upregulated [25]. The
immune response to YKL-39 was independent of that to YKL-40: the
level of YKL-40 protein did not correlate with the level of YKL-39. As it is
possible to see in Figure 4: in one case, both YKL-39 and YKL-40 were detected
in anaplastic astrocytoma; in other cases YKL-39 or YKL-40 or none of them was detected.
Western blots therefore revealed neither possible synergistic, nor simultaneous
increasing of activity of YKL-39 and YKL-40.Figure 3
Proteins YKL-39 and HC-gp39 are highly homologous (50,4%) members of 18 glicosylhydrolases family.
Amino-acid residues of YKL-40 differing from YKL-39 are boxed.Figure 4
Detection of YKL-39 and YKL-40 in tumors and normal human brain. (A) Western blot analysis of total tissue lysates with rabbit
polyclonal antibody to YKL-39. (B) Western
blot analysis of total tissue lysates with rabbit polyclonal antibody to
YKL-40. (C) Western blot
analysis of total tissue lysates with antibody toβ-actin. Tissue and tumor types are indicated above
each lane of the blot, numbers are the conditional numbers of tissue samples:
NB—human adult normal brain, Rec. protein in (A)
recombinant YKL-39, Rec. protein in (B) recombinant YKL-40, AA—anaplastic astrocytoma, A—diffuse astrocytoma, M—protein weight molecular marker (PageRuler
Unstained Protein Ladder SM0661, Fermentas), the position of the band of 40 kDa
is indicated.The increasing of YKL-39 level in
subsets of patients with glial tumors is reported and apparently represents a
cellular response to changes in the extracellular matrix environment. This,
coupled with the abnormal increase of theYKL-40 gene expression, identifies a novel molecular marker for glial tumors. Clarification
of the antibody and T cell responses to autoantigens may lead to a better
understanding of the pathophysiology of tumor development in patients with
astrocytomas. However, high oncogenic heterogeneity of brain tumors is the
considerable hindering for successful therapy of separate tumors. Continuation
of investigation of new molecular markers must help in the finding of
correlations between the changes of their activity and prognosis of motion of
disease.



---

*Source: 814849-2008-10-23.xml*